Palbociclib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. | Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. | ||
<scene name='10/1001138/Overall/ | <scene name='10/1001138/Overall/3'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]). | ||
<scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>. | <scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>. | ||
